Drug Sales Trends for INTUNIV

Annual Sales Revenues and Units Sold for INTUNIV

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
INTUNIV			2021
INTUNIV			2020
INTUNIV			2019

Market Analysis and Sales Projections for INTUNIV

Overview of INTUNIV

INTUNIV, also known as guanfacine hydrochloride, is a phenylacetyl-guanidine derivative used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. It is formulated as extended-release tablets for oral administration and is particularly indicated for patients for whom stimulants are not suitable, not tolerated, or have been shown to be ineffective[1].

Market Size and Growth

The global ADHD market, within which INTUNIV operates, is significant and growing. As of 2023, the global ADHD market size was estimated at USD 14.3 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.7% from 2024 to 2030. This growth is driven by the rising global prevalence of ADHD, increasing awareness among healthcare professionals and patients, and escalating healthcare expenditure[4].

Regional Market Performance

United States

In the U.S., the ADHD market is expected to grow at a CAGR of 5.1% from 2024 to 2032, reaching USD 24.6 billion by the end of 2032. This growth is fueled by the increasing demand for ADHD treatments and the expanding awareness and diagnosis of the disorder[3].

Europe

The European ADHD market is also on the rise, particularly driven by the prevalence of ADHD among children and adults. The European Commission has approved several ADHD drugs, including INTUNIV, which is expected to contribute to market growth in the region. The UK, in particular, is expected to see rapid growth due to underdiagnosed and undertreated ADHD cases, with efforts to increase awareness and provide diagnosis and treatment[4].

Sales Performance of INTUNIV

Recent Sales Data

In the fiscal year 2022, sales of INTUNIV showed a 17.0% increase, reaching ¥19.2 billion. This growth is part of the broader trend of increasing demand for ADHD treatments. Additionally, the transfer of ADHD drugs, including INTUNIV, to Takeda resulted in a one-time payment to Shionogi, further impacting revenue[5].

Future Projections

Given the growing demand for ADHD treatments and the specific indications and advantages of INTUNIV, it is likely that sales will continue to rise. The expansion of in-house sales capabilities and the increasing awareness and diagnosis of ADHD are key factors that will drive future sales growth.

Key Drivers of Growth

Increasing Prevalence and Awareness

The rising global prevalence of ADHD and increasing awareness among healthcare professionals and patients are significant drivers of the market. Organizations like the UK Adult ADHD Network (UKAAN) play a crucial role in providing research, training, and education, which helps in diagnosing and treating ADHD more effectively[4].

Regulatory Approvals

The approval of INTUNIV by regulatory bodies such as the European Commission has been instrumental in its market growth. Such approvals not only validate the drug's efficacy and safety but also expand its market reach[4].

Market Expansion

The expansion of in-house sales capabilities, particularly in overseas markets, is expected to contribute to the growth of INTUNIV sales. Shionogi's efforts to establish stable supplies and promote the drug in various regions will be crucial in achieving this growth[5].

Challenges and Pitfalls

Competition

The ADHD market is competitive, with several drugs available, including stimulants and non-stimulants. INTUNIV faces competition from other non-stimulant ADHD medications, which can impact its market share[4].

Generic Versions

The entry of generic versions of other ADHD drugs can reduce the sales of branded medications, including INTUNIV. For instance, the sales of Cymbalta decreased significantly due to the market entry of a generic version[5].

Financial Performance and Projections

Revenue Growth

The steady progress in sales of INTUNIV and other ADHD drugs is expected to contribute to the overall revenue growth of companies like Shionogi. The forecast indicates that the company is on track to achieve its sales targets, with a projected sales forecast of £7 billion by 2026[2].

Cost Management

Effective cost management, including the optimization of selling, general, and administrative expenses, as well as research and development expenses, will be crucial in maintaining profitability. Shionogi's plan to shift the focus of R&D expenses from COVID-19-related projects to other growth drivers is a strategic move to ensure sustainable growth[5].

Conclusion

INTUNIV is well-positioned in the growing ADHD market, driven by increasing prevalence, awareness, and regulatory approvals. While it faces competition and the potential impact of generic versions, the drug's unique indications and the expanding efforts of its manufacturers are expected to drive continued sales growth.

Key Takeaways

• Growing Market: The global ADHD market is projected to grow at a CAGR of 3.7% from 2024 to 2030.
• Regional Growth: The U.S. and European markets, particularly the UK, are expected to see significant growth due to underdiagnosed and undertreated ADHD cases.
• Sales Performance: INTUNIV has shown a 17.0% increase in sales in the fiscal year 2022.
• Key Drivers: Increasing prevalence, awareness, and regulatory approvals are key drivers of growth.
• Challenges: Competition from other ADHD medications and the impact of generic versions are potential challenges.

FAQs

Q: What is INTUNIV used for? A: INTUNIV is used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults for whom stimulants are not suitable, not tolerated, or have been shown to be ineffective.

Q: What is the projected growth rate of the global ADHD market? A: The global ADHD market is projected to grow at a CAGR of 3.7% from 2024 to 2030.

Q: Which regions are expected to see significant growth in the ADHD market? A: The U.S. and European markets, particularly the UK, are expected to see significant growth due to underdiagnosed and undertreated ADHD cases.

Q: What were the recent sales figures for INTUNIV? A: In the fiscal year 2022, sales of INTUNIV showed a 17.0% increase, reaching ¥19.2 billion.

Q: What are the key drivers of growth for INTUNIV sales? A: Increasing prevalence, awareness, and regulatory approvals are key drivers of growth for INTUNIV sales.

Sources

1. GlobalData: Net Present Value Model: Intuniv - GlobalData
2. Shionogi Inc.: 3rd Quarter of Fiscal 2023 Financial Results
3. GMI Insights: Attention Deficit Hyperactivity Disorder Market Share, 2024-2032
4. Grand View Research: Attention Deficit Hyperactivity Disorder Market Report, 2030
5. Shionogi Inc.: Consolidated Financial Results for Fiscal Year 2022 (IFRS)

Last updated: 2024-12-30